Sildenafil Tablet
Product Images NDC 53746-351
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 53746-351). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amneal Pharmaceuticals Of New York Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
1 (Sildenafil Tablets 2)
This text provides recommendations on drug interactions and fold change with a focus on Atorvastatin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir. It mentions specific AUC and Cmax values for these drugs, highlighting whether dose adjustments are needed or recommended in coadministration. The text also includes information on the relative change to Sildenafil alone and certain drug combinations that may not offer benefits in exercise capacity.*
1 (Sildenafil Tablets 3)
This document provides a list of drug interactions with recommendations for Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin, Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. It includes information on fold change, 90% CI, and suggestions for dose adjustment or coadministration. Some drugs like Bosentan and Ritonavir highlight that certain interactions are not recommended. The data also includes a graphical representation of change relative to interacting drug alone, indicating no benefit on exercise capacity when sildenafil is added to bosentan therapy.*
F7c6df1a-figure-05 (Sildenafil Tablets 4)
10.1 (Sildenafil Tablets 5)
F7c6df1a-figure-07 (Sildenafil Tablets 6)
Label (Sildenafil Tablets 7)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.